ESSA Pharma

$27.09
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.66 (+6.53%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ESSA Pharma and other stocks, options, and ETFs commission-free!

About EPIX

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada. The listed name for EPIX is ESSA Pharma Inc. Common Stock.

CEO
David R. Parkinson
Employees
25
Headquarters
Vancouver, British Columbia
Founded
2009
Market Cap
921.22M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
698.07K
High Today
$27.09
Low Today
$24.83
Open Price
$26.40
Volume
202.19K
52 Week High
$32.69
52 Week Low
$3.00

EPIX Earnings

-$0.52
-$0.35
-$0.17
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected May 6, Pre-Market

You May Also Like

AVAN=
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure